Skip to content

Heart Failure Uncovered

Ultromics provides clinically validated AI that helps diagnose complex cardiac diseases through the analysis of routine echocardiograms.

Latest News
EchoGo® Amyloidosis FDA Cleared
Latest News
EchoGo® Amyloidosis FDA Cleared

Breakthrough Technology

AI-powered HFpEF detection
Meet EchoGo® Heart Failure – the first and only diagnostic support tool for HFpEF detection, a complex and often overlooked form of heart failure. Leveraging machine learning, it analyzes hidden patterns and finds suspected findings, from a single routine echo video clip, sending insights within 20 minutes to support clinical decisions.
430
k+
cases processed so far
Clinical cases processed through EchoGo® since across healthcare institutions globally.
10
yrs
of outcome data
Algorithms developed using large, annotated datasets over 10+ years from global partnerships.
50
+
publications to date
Publications include JASE, JACC Advances, EHJ Open, JCF, among other peer-reviewed journals.
About Ultromics

Improved diagnostic accuracy and classification

Achieving a new standard of care in diagnostic precision.

Automated reports to support clinical decisions

Reports delivered in under 20 minutes.

“This novel solution applies AI to cardiovascular imaging to greatly simplify identification of patients with HFpEF, a diagnosis that can be challenging to make, and allow more expeditious treatment.”

Patricia A. Pellikka, M.D. , Vice Chair, Department of Cardiovascular Medicine at Mayo Clinic

The EchoGo® platform

The EchoGo® platform operates seamlessly in the background, running Ultromics’ medical devices at scale. Designed to integrate effortlessly into your workflow, EchoGo® connects with your existing infrastructure and provides seamless access to reports.

Integrate Seamlessly

  • Easily implemented, with no hardware/software at site.

  • Integrates with existing workflows and IT stacks.

  • Secure cloud VPN connection and data anonymized.

Analyze Data

  • EchoGo® powers FDA-cleared medical devices, including EchoGo® Heart Failure and EchoGo® Amyloidosis.

  • Returns structured reports via automated DICOM workflow.

  • Reports are sent to PACS and available for the interpreting physician.

Get Reimbursed

  • Inpatient: NTAP Code ICD-10 XXE2X19 – $1,000 per analysis (Medicare-covered).

  • Outpatient: HCPCS Code C9786, Clinical APC Code 574 – $285 per analysis (covered by Medicare and select commercial insurers).

Scale with Ease

  • Deploy Ultromics’ medical devices across any care setting—from hospitals to clinics—without workflow disruption.

  • Minimal training to onboard new staff with ease.

Working with global leaders to deliver
transformative outcomes

Each of our partners are innovation leaders are working with us to improve care. We partner with exceptional leaders across all stages to build transformative technologies.

Clinically Proven and FDA-cleared 


Ultromics’ AI is trained on over a decade of outcome data to support reliable identification of potential cardiac abnormalities on echocardiograms. Recognized for its transformative impact, the technology has received Breakthrough Device Designation and clearance by the FDA.

Heart Failure Logo

Up to 64% of HFpEF patients may be undiagnosed2

Proven to detect HFpEF with
90% sensitivity and 86% specificity1

Learn more
Heart Failure
fda-cleared-cropped
EchoGoAmyloidosis

Cardiac amyloidosis typically requires patients to have 5 or more medical visits before a diagnosis is made.

Proven to detect CA with 84.5% sensitivity and 89.7% specificity.

Learn more
Amyloidosis
fda-cleared-cropped

EchoGo® Heart Failure is reimbursable

Inpatient: $1,000 | Outpatient: $299

Learn more

“EchoGo® Amyloidosis is going to be revolutionary, based upon the volume of undiagnosed patients that are out there. It’s going to undoubtedly detect patients and impact morbidity and mortality for this disease.”

Faizi A. Jamal, MD, FACC , Chief, Division of Cardiology Director, Non-Invasive Cardiology Laboratory Associate Clinical Professor, Department of Medicine

Leading innovation with scientific excellence and clinical validation

4 FDA clearances & 2 break through device designations
Routed in scientific excellence from the University of Oxford by leaders in medical imaging, cardiology and AI.
Technology developed with our partners at Mayo Clinic and tested in real-world settings with leading healthcare sites
Adhering to the highest standards of quality and safety with ISO ISO13485 certification

We are redefining heart failure as we know it

Innovation is at the heart of everything we do

At the heart of our mission is a commitment to making heart failure detection easier for providers and prognosis better for patients. Healthcare professionals should receive critical information they need minimizing the added risks and costs of untreated patients or further procedures. Staying true to the standards set by our Oxford University origins, we are partnering with the most trusted and validated medical organizations in the world to improve quality of life and reduce the burden on the healthcare system at large.

“The FNIH will harness valuable perspectives and expertise of a select number of collaborations, including Ultromics, to alleviate this unmet need and pave the way for better classification and more precise treatment strategies.”

Dr Julie Gerberding , Chief Executive Officer at the FNIH

[1] Gerber Y, Weston SA, Redfield MM, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Internal Medicine. 2015;175:996–1004. [2] Savarese G and Lund LH. Global public health burden of heart failure. Cardiac Failure Review. 2017;3:1:7-11. [3] Borlaug, BA, Sharma K, Shah SJ, et al. Heart failure with preserved ejection fraction, :JACC Scientific Statement. Journal of the American College of Cardiology. 2023;81:1810–1834. [4] Akerman AP, Porumb M, Beqiri A, et al. Comparison of clinical algorithms and artificial intelligence applied to an echocardiogram to categorize risk of heart failure with preserved ejection fraction. Journal of the American College of Cardiology. ACC. 2023;81 (8_Supplement) 360.

Curious about how Ultromics can support your facility?

Request a meeting with us to learn more 

Meet with us